ArticleInternational medical case reports journal2026
Treatment of High-Risk Idiopathic Membranous Nephropathy with Huaier Granules and RASi: A Case Series.
Article in International medical case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huaier Granules, an aqueous extract preparation of Trametes robiniophila Murr, has been verified effective in treating various malignant tumors. Many agents used for membranous nephropathy, including cyclophosphamide and rituximab (RTX), were initially developed for cancer therapy. However, no previous studies have explored its application in adult idiopathic membranous nephropathy (IMN). This case series analyzed clinical data of 2 high-risk IMN patients admitted to our hospital from 2023 to 2026. All patients were confirmed by renal biopsy and anti-phospholipase A2 receptor (anti-PLA2R) antibody testing. They received combined therapy of Huaier Granules plus renin-angiotensin system inhibitors (RASi) as the basic treatment. After over 12 months of treatment, laboratory results showed negative anti-PLA2R antibody levels; 24-hour urinary protein, serum albumin and estimated glomerular filtration rate (eGFR) were improved compared with baseline. Case 1 was followed up for 25 months and Case 2 was followed up for 21 months. Case 1 achieved complete clinical remission and Case 2 partial remission. No obvious adverse reactions related to Huaier Granules were observed, with good patient tolerance. This regimen may provide a new adjuvant therapeutic strategy for clinical management of IMN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.